Legal status in the United States

Is Retatrutide legal?

Read at FDA, DEA and WADAPublished by PepVault

Retatrutide has no FDA-approved product (it is in phase 3 trials), is not a federally controlled substance, and is not named on WADA’s Prohibited List (from January 1, 2027, its S0 class names peptides in general), as of November 18, 2026.

Retatrutide at a glance

CheckStatus, read Nov 18, 2026
FDA approvalNot approved; in phase 3 trials
CompoundingBarred from compounding (FDA)
DEA scheduleNot controlled
Sport (WADA)Not named; from 2027, S0 names peptides in general

FDA approval

Retatrutide has no FDA-approved product: Drugs@FDA lists no application for it, and FDA writes that it is not a component of any FDA-approved drug.

In clinical trials

Eli Lilly has run and is running phase 3 trials of it: ClinicalTrials.gov lists 14 phase 3 studies of retatrutide sponsored by Lilly, for obesity, type 2 diabetes, heart and kidney outcomes; 5 are completed and 9 are active or recruiting.

A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Compounding

FDA writes that retatrutide cannot be used in compounding under federal law, and that it has warned telehealth companies, ingredient distributors and outsourcing facilities over it.

The source: “Retatrutide and cagrilintide cannot be used in compounding under federal law.”

DEA schedule

It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

Sport (WADA)

Until December 31, 2026: The 2026 Prohibited List doesn’t name retatrutide. S0 bans any substance not covered elsewhere on the list that has “no current approval by any governmental regulatory health authority for human therapeutic use”; whether that reaches it turns on its approval outside the United States, which this page doesn’t cover. From January 1, 2027: WADA’s 2027 list adds “peptides” to S0’s examples of non-approved substances, and its explanatory note says a peptide not named on the list “may still be prohibited”. It still doesn’t name retatrutide, and whether S0 reaches it still turns on its approval outside the United States.

How it is sold when it isn’t approved

FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.

The source: falsely labeled “for research purposes” or “not for human consumption.”

What this means and doesn’t

This page reports what the agencies’ own pages said about Retatrutide in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.

It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.

Questions

  • Is Retatrutide FDA approved?

    Retatrutide has no FDA-approved product: Drugs@FDA lists no application for it, and FDA writes that it is not a component of any FDA-approved drug. Eli Lilly has run and is running phase 3 trials of it: ClinicalTrials.gov lists 14 phase 3 studies of retatrutide sponsored by Lilly, for obesity, type 2 diabetes, heart and kidney outcomes; 5 are completed and 9 are active or recruiting.

  • Is Retatrutide a controlled substance?

    It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

  • Is Retatrutide banned in sport?

    Until December 31, 2026: The 2026 Prohibited List doesn’t name retatrutide. S0 bans any substance not covered elsewhere on the list that has “no current approval by any governmental regulatory health authority for human therapeutic use”; whether that reaches it turns on its approval outside the United States, which this page doesn’t cover. From January 1, 2027: WADA’s 2027 list adds “peptides” to S0’s examples of non-approved substances, and its explanatory note says a peptide not named on the list “may still be prohibited”. It still doesn’t name retatrutide, and whether S0 reaches it still turns on its approval outside the United States.

  • What does FDA say about compounding Retatrutide?

    FDA writes that retatrutide cannot be used in compounding under federal law, and that it has warned telehealth companies, ingredient distributors and outsourcing facilities over it.

  • What does FDA say about the “research use only” label?

    FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.

Read next

Track it in the app

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo